Of the many nontuberculous mycobacteria only two cause frequent significant pulmonary disease in man. M kansasii infection is more often seen in this country but is not a major clinical problem as there is a good response to antituberculosis drugs. Mycobacteria of the M avium-intracellulare complex however present a management problem to the clinician as the disease they cause varies from low grade colonisation of lung to a progressive destruction of lung and death. There are numerous reports of poor response to therapy.' Strains within the complex are usually sensitive to ethionamide, often to cycloserine and clofazamine, and show borderline resistance to ethambutol. There is resistance in vitro to all other drugs. Thus when he encounters a patient with this infection a physician is faced with the problem of whether to treat the patient and which drugs to use. 
Methods

Results
NO TREATMENT GROUP
Thirteen patients received no specific antituberculosis chemotherapy at any time in their illness. There were seven men and six women with a mean age of 61 years (range 37-76 years).
Seven were symptomatic at presentation; six had progressive disease, of whom three have subsequently died. The seventh is stable but has only been followed up for two years.
Six patients were asymptomatic at the time of diagnosis. All appeared to be stable on follow-up, but four have been under review for only two years, a relatively short period in the natural history of the disease. 
Results of therapy in symptomatic and asymptomatic patients
The results for all patients have been combined and are given in tables 2 and 3. Table 2 shows that in symptomatic patients the natural history is that of progressive disease. Effective therapy appears to have been achieved with isoniazid and rifampicin plus either ethambutol or streptomycin as a third drug but not with other regimens. In view of the relapse of three patients given between 12 and 18 months therapy it would seem advisable to give 24 months therapy to all patients.
The disease in asymptomatic patients did not necessarily progress but could do so, and both those who did so died of their disease. In some the follow-up period was short and we cannot be certain that progression will not occur. 
Discussion
